(Q28181807)

1

0 references

Raymond G Schlienger

2

0 references

Christian M Matter

3

0 references

Christoph R Meier

Atherosclerosis — An Inflammatory Disease

5

0 references

language of work or name

English

0 references

publication date

April 2005

0 references

published in

Pharmacotherapy

0 references

volume

25

0 references

issue

4

0 references

page(s)

503-10

0 references

cites work

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Effect of ibuprofen on cardioprotective effect of aspirin

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction

22 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.25.4.503.61021

Inflammation in atherosclerosis

22 April 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Atherosclerosis. the road ahead

22 April 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

The coxibs, selective inhibitors of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Association between naproxen use and protection against acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Use of the UK General Practice Research Database for pharmacoepidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Validation of information recorded on general practitioner based computerised data resource in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Validity of the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Antibiotics and risk of subsequent first-time acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Acute respiratory-tract infections and risk of first-time acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

C-reactive protein and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.503.61021

10.1592/PHCO.25.4.503.61021

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_22z3evb3yvbrlgecsp65wv4eri

2484118

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/22z3evb3yvbrlgecsp65wv4eri

mapped directly with Wikidata item

24 November 2022

based on heuristic

2484118

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference